FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004041608> ?p ?o ?g. }

• W2004041608 abstract "Abstract Background We have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of mucosal PGE 2 and are protected against colitis-associated neoplasia. However, it is still unclear whether PGE 2 is the central factor downstream of TLR4 signaling that promotes intestinal tumorigenesis. To further elucidate critical downstream pathways involving TLR4-mediated intestinal tumorigenesis, we examined the effects of exogenously administered PGE 2 in TLR4-/- mice to see if PGE 2 bypasses the protection from colitis-associated tumorigenesis. Method Mouse colitis-associated neoplasia was induced by azoxymethane (AOM) injection followed by two cycles of dextran sodium sulfate (DSS) treatment. Two different doses of PGE 2 (high dose group, 200 μg, n = 8; and low dose group, 100 μg, n = 6) were administered daily during recovery period of colitis by gavage feeding. Another group was given PGE 2 during DSS treatment (200 μg, n = 5). Inflammation and dysplasia were assessed histologically. Mucosal Cox-2 and amphiregulin (AR) expression, prostanoid synthesis, and EGFR activation were analyzed. Results In control mice treated with PBS, the average number of tumors was greater in WT mice (n = 13) than in TLR4-/- mice (n = 7). High dose but not low dose PGE 2 treatment caused an increase in epithelial proliferation. 28.6% of PBS-treated TLR4-/- mice developed dysplasia (tumors/animal: 0.4 ± 0.2). By contrast, 75.0% (tumors/animal: 1.5 ± 1.2, P < 0.05) of the high dose group and 33.3% (tumors/animal: 0.3 ± 0.5) of the low dose group developed dysplasia in TLR4-/- mice. Tumor size was also increased by high dose PGE 2 treatment. Endogenous prostanoid synthesis was differentially affected by PGE 2 treatment during acute and recovery phases of colitis. Exogenous administration of PGE 2 increased colitis-associated tumorigenesis but this only occurred during the recovery phase. Lastly, PGE 2 treatment increased mucosal expression of AR and Cox-2, thus inducing EGFR activation and forming a positive feedback mechanism to amplify mucosal Cox-2. Conclusions These results highlight the importance of PGE 2 as a central downstream molecule involving TLR4-mediated intestinal tumorigenesis." @default.
• W2004041608 created "2016-06-24" @default.
• W2004041608 creator A5001114801 @default.
• W2004041608 creator A5012357829 @default.
• W2004041608 creator A5017394429 @default.
• W2004041608 creator A5017538889 @default.
• W2004041608 creator A5019034672 @default.
• W2004041608 creator A5023821870 @default.
• W2004041608 creator A5030494836 @default.
• W2004041608 creator A5033087694 @default.
• W2004041608 creator A5053396881 @default.
• W2004041608 creator A5058765577 @default.
• W2004041608 creator A5066894712 @default.
• W2004041608 creator A5077530369 @default.
• W2004041608 date "2010-07-16" @default.
• W2004041608 modified "2023-10-10" @default.
• W2004041608 title "The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia" @default.
• W2004041608 cites W1648593433 @default.
• W2004041608 cites W1918606482 @default.
• W2004041608 cites W1968537403 @default.
• W2004041608 cites W1971281137 @default.
• W2004041608 cites W1976875629 @default.
• W2004041608 cites W1982248155 @default.
• W2004041608 cites W1994659489 @default.
• W2004041608 cites W1995260103 @default.
• W2004041608 cites W1995799117 @default.
• W2004041608 cites W1996652335 @default.
• W2004041608 cites W1998050886 @default.
• W2004041608 cites W2000009498 @default.
• W2004041608 cites W2004682588 @default.
• W2004041608 cites W2016264364 @default.
• W2004041608 cites W2018728235 @default.
• W2004041608 cites W2025482435 @default.
• W2004041608 cites W2035475717 @default.
• W2004041608 cites W2041769554 @default.
• W2004041608 cites W2044701263 @default.
• W2004041608 cites W2050294746 @default.
• W2004041608 cites W2055951936 @default.
• W2004041608 cites W2060467273 @default.
• W2004041608 cites W2062394418 @default.
• W2004041608 cites W2069625879 @default.
• W2004041608 cites W2071498782 @default.
• W2004041608 cites W2082590423 @default.
• W2004041608 cites W2083362070 @default.
• W2004041608 cites W2097733438 @default.
• W2004041608 cites W2097809605 @default.
• W2004041608 cites W2097953937 @default.
• W2004041608 cites W2106293055 @default.
• W2004041608 cites W2111439621 @default.
• W2004041608 cites W2113720139 @default.
• W2004041608 cites W2121573116 @default.
• W2004041608 cites W2125471013 @default.
• W2004041608 cites W2125594974 @default.
• W2004041608 cites W2125795237 @default.
• W2004041608 cites W2127810970 @default.
• W2004041608 cites W2130264265 @default.
• W2004041608 cites W2133644846 @default.
• W2004041608 cites W2134234269 @default.
• W2004041608 cites W2145719229 @default.
• W2004041608 cites W2150586689 @default.
• W2004041608 cites W2152625137 @default.
• W2004041608 cites W2158930367 @default.
• W2004041608 cites W2162037098 @default.
• W2004041608 cites W2166281548 @default.
• W2004041608 cites W2336215030 @default.
• W2004041608 cites W336987180 @default.
• W2004041608 cites W4243630079 @default.
• W2004041608 doi "https://doi.org/10.1186/1471-230x-10-82" @default.
• W2004041608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2912804" @default.
• W2004041608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20637112" @default.
• W2004041608 hasPublicationYear "2010" @default.
• W2004041608 type Work @default.
• W2004041608 sameAs 2004041608 @default.
• W2004041608 citedByCount "38" @default.
• W2004041608 countsByYear W20040416082012 @default.
• W2004041608 countsByYear W20040416082013 @default.
• W2004041608 countsByYear W20040416082014 @default.
• W2004041608 countsByYear W20040416082015 @default.
• W2004041608 countsByYear W20040416082016 @default.
• W2004041608 countsByYear W20040416082017 @default.
• W2004041608 countsByYear W20040416082018 @default.
• W2004041608 countsByYear W20040416082020 @default.
• W2004041608 countsByYear W20040416082022 @default.
• W2004041608 countsByYear W20040416082023 @default.
• W2004041608 crossrefType "journal-article" @default.
• W2004041608 hasAuthorship W2004041608A5001114801 @default.
• W2004041608 hasAuthorship W2004041608A5012357829 @default.
• W2004041608 hasAuthorship W2004041608A5017394429 @default.
• W2004041608 hasAuthorship W2004041608A5017538889 @default.
• W2004041608 hasAuthorship W2004041608A5019034672 @default.
• W2004041608 hasAuthorship W2004041608A5023821870 @default.
• W2004041608 hasAuthorship W2004041608A5030494836 @default.
• W2004041608 hasAuthorship W2004041608A5033087694 @default.
• W2004041608 hasAuthorship W2004041608A5053396881 @default.
• W2004041608 hasAuthorship W2004041608A5058765577 @default.
• W2004041608 hasAuthorship W2004041608A5066894712 @default.
• W2004041608 hasAuthorship W2004041608A5077530369 @default.
• W2004041608 hasBestOaLocation W20040416081 @default.
• W2004041608 hasConcept C121608353 @default.
• W2004041608 hasConcept C126322002 @default.

• next